CTX 100

Drug Profile

CTX 100

Alternative Names: ETX 100; Hyaluronan inhalation - Actelion Pharmaceuticals; Hyaluronic acid inhalation - Actelion Pharmaceuticals

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoTherix
  • Class Anti-inflammatories
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alpha 1-antitrypsin deficiency; Asthma

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
  • 14 Apr 2005 Discontinued - Phase-I for Alpha 1-antitrypsin deficiency in Netherlands (Inhalation)
  • 14 Apr 2005 Discontinued - Phase-I for Asthma in Netherlands (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top